thrombospondin type 1 domain containing 7AGenealiases: []
Q-omics provides the consensus-scored THSD7A profile across patient tissues and cancer cell-line models. THSD7A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, THSD7A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, THSD7A protein abundance shows 21,839 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, and BRCA as cancer lineages where THSD7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THSD7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THSD7A survival associations across molecular data types. THSD7A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THSD7A RNA expression–survival associations across cancer types. High THSD7A expression shows unfavorable associations in UVM, BLCA, THCA, STAD and KIRP, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for THSD7A RNA expression.
This table summarizes THSD7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for THSD7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THSD7A shows lower tumor expression in KIRC, KIRP, UCEC, LUSC, BRCA and LUAD. The KIRC box plot shows higher THSD7A RNA expression in normal versus tumor tissue (log2 FC = −2.015, t-test p < 0.001).
This table shows molecular features associated with THSD7A in patient tissues and cancer cell lines. In patient samples, THSD7A shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, THSD7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
